On October 2, 2018, Yuan, Hong; Li, Si; Zhao, Jingyuan; Wu, Xiangdong; Wang, Xiaoxi; Wang, Nan; Yao, Bingjie; Zhao, Dan; Yao, Yao; Sun, Xiuli; Ma, Xiaodong published a patent.Safety of N-(3-Aminophenyl)acrylamide The title of the patent was Pyrimidine compound, composition and its application in treatment of lymphoma leukemia. And the patent contained the following:
The invention disclosed a kind of pyrimidine derivative, its preparation method and application as Bruton’s tyrosine kinase inhibitor. The claimed pyrimidine derivative is shown in structure I (R = H, Cl, F, or trifluoromethyl; R1 = H, Cl or F; M = amido group). The claimed compound is prepared via multiple steps (procedure given). The prepared compound can inhibiting Bruton’s tyrosine kinase, can be used for treating Burkitt’s lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma or chronic lymphocytic leukemia. The experimental process involved the reaction of N-(3-Aminophenyl)acrylamide(cas: 16230-24-3).Safety of N-(3-Aminophenyl)acrylamide
The Article related to pyrimidine derivative preparation brutons tyrosine kinase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Safety of N-(3-Aminophenyl)acrylamide
Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics